New Launch17 Apr 2025, 12:56 am
Glenmark Pharmaceuticals Inc., USA to Launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Anticipating $421.7 Million Market
AI Summary
Glenmark Pharmaceuticals Inc., USA is set to launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg in May 2025. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Adderall®? Tablets, of Teva Women’s Health, Inc. The Adderall® Tablets market achieved annual sales of approximately $421.7 million as per IQVIA™ sales data for the 12-month period ending February 2025. Glenmark's move aims to help alleviate the shortage of this highly prescribed medication in the United States.
Key Highlights
- Glenmark Pharmaceuticals Inc., USA to launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets in May 2025.
- The product is bioequivalent and therapeutically equivalent to the reference listed drug, Adderall®? Tablets, of Teva Women’s Health, Inc.
- The Adderall® Tablets market achieved annual sales of approximately $421.7 million as per IQVIA™ sales data for the 12-month period ending February 2025.
- Glenmark's launch aims to help alleviate the shortage of this highly prescribed medication in the United States.
- Glenmark is a research-led, global pharmaceutical company with a presence across Branded, Generics, and OTC segments.